Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Elagolix (Primary)
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- Sponsors AbbVie
- 20 Nov 2017 Planned End Date changed from 17 May 2019 to 29 Mar 2019.
- 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2017 Planned End Date changed from 16 Jul 2019 to 17 May 2019.